EA
SYRE icon

Ellsworth Advisors’s Spyre Therapeutics SYRE Stock Holding History

Ellsworth Advisors’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.69M Sell
16,553
-5,410
-25% -$395K 0.28% 85
2026
Q1 		$1.11M Buy
+21,963
New +$828K 0.21% 93

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Ellsworth Advisors's SYRE Position: Q2 2026 in Review

Ellsworth Advisors reduced its Spyre Therapeutics (SYRE) stake by 25% in Q2 2026, selling an estimated $395K and leaving 16,553 shares worth $1.69M. The position accounts for 0.28% of the portfolio, ranked #85.

Ellsworth Advisors first reported a position in SYRE in Q1 2026 and has held it in 2 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Ellsworth Advisors held 16,553 shares of Spyre Therapeutics worth $1.69M as of Q2 2026.
  • Ellsworth Advisors sold 5,410 Spyre Therapeutics shares in Q2 2026, an estimated $395K.
  • Spyre Therapeutics made up 0.28% of Ellsworth Advisors's portfolio in Q2 2026, its #85 holding.
  • Ellsworth Advisors first reported a position in Spyre Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Ellsworth Advisors's 13F filing for Q2 2026, filed 16 Jul 2026.